Next earnings date: 22 Oct 2025
– NASDAQ:RDUS
stock price today
$30
+14.77
+96.98%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 1 day
stock price monthly change
-8.36%
month
stock price quarterly change
-8.36%
quarter
stock price yearly change
-51.82%
year
key metrics
Market Cap | 440.01M |
Enterprise value | 820.46M |
P/E | -9.81 |
EV/Sales | 0.58 |
EV/EBITDA | -441.82 |
Price/Sales | 0.30 |
Price/Book | 0.48 |
PEG ratio | 0.38 |
EPS | -0.92 |
Revenue | 2.95B |
EBITDA | 33.79M |
Income | -25.96M |
Revenue Q/Q | 12.38% |
Revenue Y/Y | 85.40% |
Profit margin | -3.15% |
Oper. margin | -3.35% |
Gross margin | 9.31% |
EBIT margin | -3.35% |
EBITDA margin | 1.14% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freestock price history
stock forecast
financial statements
| Feb 2023 | 755.95M | 4.35M | 0.58% |
|---|---|---|---|
| May 2023 | 809.61M | 13.46M | 1.66% |
| Aug 2023 | 717.93M | -25.81M | -3.6% |
| Nov 2023 | 672.89M | -17.96M | -2.67% |
| May 2023 | 809.61M | 13.46M | 1.66% |
|---|---|---|---|
| Aug 2023 | 717.93M | -25.81M | -3.6% |
| Nov 2023 | 672.89M | -17.96M | -2.67% |
| Aug 2025 | 713M | 5.64M | 0.79% |
Analysts Price target
Financials & Ratios estimates
| 2024-10-24 | -0.79 | -0.41 |
|---|
Paying a dividend while loss making.
4.92%
Yield TTM
| Payout ratio | -24.47% |
|---|
| 2019 | |
|---|---|
| 2020 | 3.82% |
| 2021 | 1.61% |
| 2022 | 2.29% |
| 2023 | 2.28% |
| Feb 2023 | 1781095000 | 852.65M | 47.87% |
|---|---|---|---|
| May 2023 | 1866428000 | 926.83M | 49.66% |
| Aug 2023 | 1715949000 | 804.29M | 46.87% |
| Nov 2023 | 1692654000 | 808.37M | 47.76% |
| Feb 2023 | 87.84M | -26.18M | -53.71M |
|---|---|---|---|
| May 2023 | -21.16M | -19.01M | 33.21M |
| Aug 2023 | 134.83M | -26.57M | -106.76M |
| Nov 2023 | -1.29M | -24.19M | 23.81M |
alternative data
| Aug 2023 | 293 |
|---|---|
| Sep 2023 | 293 |
| Oct 2023 | 293 |
| Nov 2023 | 293 |
| Dec 2023 | 293 |
| Jan 2024 | 293 |
| Feb 2024 | 293 |
| Mar 2024 | 293 |
| Apr 2024 | 293 |
| May 2024 | 293 |
| Jun 2024 | 3,353 |
| Jul 2024 | 3,353 |
other data
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2024 | 0 | 1021 |
| Oct 2024 | 0 | 17675 |
| Nov 2024 | 0 | 10379 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | HEISKELL STEVEN officer: SVP & Pr.. | Class A Common Stock | 9,000 | $19.52 | $175,680 | ||
Sale | VAUGHN JAMES MATTHEW officer: SVP, GC,.. | Class A Common Stock | 1,379 | $16.63 | $22,933 | ||
Sale | HEISKELL STEVEN officer: SVP & Pr.. | Class A Common Stock | 17,675 | $17.08 | $301,889 | ||
Sale | GAGGINI STEFANO R. officer: SVP, CFO | Class A Common Stock | 1,021 | $18.57 | $18,960 | ||
Purchase | RUBRIC CAPITAL MANAGEMENT LP 10 percent owner | Common Stock, par value $0.0001 per share ("Common Stock") | 1,678,954 | $10.07 | $16,907,067 | ||
Purchase | RUBRIC CAPITAL MANAGEMENT LP 10 percent owner | Common Stock, par value $0.0001 per share ("Common Stock") | 4,012 | $10.07 | $40,401 | ||
Purchase | BIOTECH TARGET N V 10 percent owner | Common Stock | 477,824 | $5.57 | $2,661,002 | ||
Purchase | BIOTECH TARGET N V 10 percent owner | Common Stock | 300,000 | $6.32 | $1,894,500 | ||
Purchase | BIOTECH TARGET N V 10 percent owner | Common Stock | 250,000 | $6.3 | $1,574,750 | ||
Purchase | RUBRIC CAPITAL MANAGEMENT LP 10 percent owner | Common Stock, par value $0.0001 per share ("Common Stock") | 146,685 | $7.08 | $1,037,796 |
| Patent |
|---|
Application METHODS FOR DETECTING NEUTRALIZING ANTIBODIES TO PARATHYROID HORMONE (PTH) AND PARATHYROID HORMONE-RELATED PEPTIDE (PTHRP) ANALOG Filling date: 7 Jan 2022 Issue date: 30 Jun 2022 |
Application Filling date: 11 Mar 2022 Issue date: 23 Jun 2022 |
Application Filling date: 10 Sep 2021 Issue date: 28 Apr 2022 |
Application Filling date: 1 Apr 2021 Issue date: 6 Jan 2022 |
Application METHODS FOR DETECTING NEUTRALIZING ANTIBODIES TO PARATHYROID HORMONE (PTH) AND PARATHYROID HORMONE-RELATED PEPTIDE (PTHRP) ANALOG Filling date: 7 Jul 2021 Issue date: 16 Dec 2021 |
Application Filling date: 6 Aug 2021 Issue date: 9 Dec 2021 |
Application Filling date: 23 Mar 2021 Issue date: 2 Dec 2021 |
Grant Filling date: 28 Aug 2019 Issue date: 4 May 2021 |
Grant Filling date: 3 Jan 2020 Issue date: 20 Apr 2021 |
Application Filling date: 31 Aug 2020 Issue date: 25 Feb 2021 |
| Quarter | Transcript |
|---|---|
| Q2 2024 4 Apr 2024 | Q2 2024 Earnings Call Transcript |
| Q1 2024 4 Jan 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 25 Oct 2023 | Q4 2023 Earnings Call Transcript |
| Q2 2023 5 Apr 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. G. Kelly Martin (1959) Chief Executive Officer, Pres & Director | $612,370 |
Mr. Salvador Grausso III (1975) Senior Vice President & Head of U.S. Patient access | $530,420 |
-
What's the price of stock today?
One share of stock can currently be purchased for approximately $30.
-
When is 's next earnings date?
null is estimated to report earnings on Wednesday, 22 Oct 2025.
-
Does pay dividends?
Yes, pays dividends and its trailing 12-month yield is 4.92% with -24% payout ratio.It means that the company is paying a dividend while loss making. The last stock dividend of undefined was paid on 6 Sep 2025.
-
How much money does make?
has a market capitalization of 440.01M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 17.32% to 2.88B US dollars. made a loss 25.79M US dollars in net income (profit) last year or -$0.41 on an earnings per share basis.
-
What is 's stock symbol?
null is traded on the NASDAQ under the ticker symbol "RDUS".
-
What is 's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of ?
Shares of can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are 's key executives?
's management team includes the following people:
- Mr. G. Kelly Martin Chief Executive Officer, Pres & Director(age: 66, pay: $612,370)
- Mr. Salvador Grausso III Senior Vice President & Head of U.S. Patient access(age: 50, pay: $530,420)
-
How many employees does have?
As Jul 2024, employs 3,353 workers, which is 1044% more then previous quarter.
-
When went public?
null is publicly traded company for more then 11 years since IPO on 6 Jun 2014.
-
What is 's official website?
The official website for is radiuspharm.com.
-
Where are 's headquarters?
is headquartered at 950 Winter St, Waltham, MASSACHUSETTS.
-
How can i contact ?
's mailing address is 950 Winter St, Waltham, MASSACHUSETTS and company can be reached via phone at +1 617 551 4000.
company profile:
Exchange:
NASDAQ
Full time employees:
3,011
Industry:
Drug Manufacturers - Specialty & Generic
Sector:
Healthcare
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts. As of August 10, 2022, Radius Health, Inc. was taken private.
950 Winter St
Waltham, MASSACHUSETTS 02210
Waltham, MASSACHUSETTS 02210
CIK: 0001428522
ISIN: US7504692077
CUSIP: 750469207
